Skip to main content

Zoetis Inc Cl A(ZTS-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low175.98
Day High179.46
Open:176.25
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Motley Fool
Zoetis (ZTS) Q3 2023 Earnings Call Transcript
The Globe and Mail
18 U.S. stocks for turbulent times
Motley Fool
4 Top Dividend Growth Stocks of the S&P 500 That Have Major Long-Term Potential for Investors
Motley Fool
Zoetis (ZTS) Q2 2023 Earnings Call Transcript
Barchart
Stock Index Futures Plunge as China Trade Data Disappoints, Moody's Downgrades U.S. Banks
MarketBeat
MarketBeat Week in Review – 07/31 - 08/04
Baystreet
Macro Figures Sparse in Canada During Short Week
MarketBeat
Rising Dividend Make Zoetis a Doggone Winner
Motley Fool
2 Healthcare Stocks That Could Make You Richer
SYNDTGAM
Relentless U.S. stock rally faces Fed test
Motley Fool
2 Dividend Stocks That Doubled Their Payouts in 5 Years
Barchart
Act Fast! These Buy Rated Companies Just Crossed Over Above Their 200-Day SMA!
MarketBeat
PetVivo Sales Spryng Higher on Injectable OA Relief for Pets
Motley Fool
History Suggests This S&P 500 Dividend Stock Is Perfect to Buy and Hold Forever
MarketBeat
Bullish or Bearish? Vetting Animal Health Care Stocks
The Globe and Mail
Expanding array of services for pets offers investors chance to get in on sector’s growth
MarketBeat
Zoetis Declares New Dividend, Hinting At Undervaluation
Business Wire
Zoetis Announces U.S. FDA Approval of Librela™ (bedinvetmab injection) to Control Osteoarthritis (OA) Pain in Dogs
Motley Fool
Zoetis (ZTS) Q1 2023 Earnings Call Transcript
Business Wire
Zoetis Announces First Quarter 2023 Results
Business Wire
Zoetis Announces Date for 2023 Investor Day
Motley Fool
5 Women-Led Businesses Absolutely Crushing the Stock Market Right Now
Motley Fool
Why These 2 Vet Med Stocks Are Surging
Business Wire
Zoetis Foundation Announces First Round of 2023 Grants to Advance Farmer and Veterinarian Education, Livelihoods and Well-being
The Globe and Mail
6 companies benefiting from the pandemic pet boom
Business Wire
Zoetis to Host Webcast and Conference Call on First Quarter 2023 Financial Results
Business Wire
Zoetis Named One of the World’s Most Ethical Companies by Ethisphere
The Globe and Mail
Why agriculture commodities are a good long-term bet
Business Wire
Zoetis to Participate in the TD Cowen Health Care Conference
Business Wire
Zoetis Secures $15.3 Million Grant to Advance Sustainable Livestock Production and Improve Livelihoods in Sub-Saharan Africa
Business Wire
Zoetis to Participate in the Bank of America Securities 2023 Animal Health Summit
Motley Fool
3 Stocks to Avoid This Week

Profile

Zoetis Inc. is a leader in the animal health space with a focus on both livestock and companion animals in seven major product categories: vaccines, anti-infectives, parasiticides, dermatology, other pharmaceutical products, medicated feed additives and animal health diagnostics. Zoetis has a diversified business, which caters to eight core species ' cattle, swine, poultry, fish and sheep (collectively, livestock) and dogs, cats and horses (collectively, companion animals). It directly markets its products to veterinarians and livestock producers. The outstanding growth rate in the companion animal medicines, vaccines and diagnostics sector is being driven by economic development, related increases in disposable income and a rise in pet ownership and spending on pet care.Zoetis has been working on strengthening its product portfolio through acquisitions and deals.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2023.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2023 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.